New drugs make headway against lung, prostate, colon cancers

The key issue to the costs quoted with these new drugs is that they are the highly inflated rates charged by the drug companies to private US hospitals and insurance companies.

Countries with government funded public healthcare systems slash these costs by negotiating in bulk for these drugs, and thereby slashing the costs.

Another way U.S. consumers get screwed.